comparemela.com
Home
Live Updates
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease -October 27, 2023 at 09:26 am EDT
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer -targeting antibody, to inform dose selection, plus further analyses of...
Related Keywords
Boston ,
Massachusetts ,
United States ,
Jessica Laub ,
Eric Siemers ,
Alex Braun ,
Stephen Salloway ,
Daniel Oconnell ,
Acumen Pharmaceuticals Inc ,
Development Of Novel Bioanalytical Assays ,
Nasdaq ,
Exchange Commission ,
Alpert Medical School Of Brown University ,
Drug Administration ,
Annual Clinical Trials ,
Danielo Connell ,
Chief Executive Officer ,
Target Engagement ,
Various Doses ,
Amyloid Plaque Load ,
Higher Doses ,
Did Not Develop ,
Alpert Medical School ,
Brown University ,
Chief Medical Officer ,
Novel Bioanalytical Assays ,
Additional Analyses Using ,
Sensitive Assay ,
O Selective Antibody ,
Fast Track ,
Acumen Pharmaceuticals ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Report ,
Markets ,